For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  Inclusion Criteria:  Diagnosis of discoid/subacute cutaneous lupus erythematosus (DLE/SCLE) for at least 3 months prior to screening visit Meets both clinical and histopathological diagnostic cutaneous lupus erythematosus (CLE) criteria per protocol Currently receiving treatment for DLE/SCLE with a stable regimen of at least one of the following medications: oral corticosteroid, and/or antimalarial, and/or immunosuppressant  Exclusion Criteria:  Women who are pregnant, lactating, breastfeeding or planning pregnancy during the study period Any of the following specific CLE subtypes in isolation: acute cutaneous lupus erythematosus (ACLE), lupus tumidus, lupus (profundus) panniculitis, chilblains Drug-induced CLE and/or drug-induced systemic lupus erythematosus (SLE) Antiphospholipid antibody syndrome, serious thrombotic event or unexplained pregnancy loss within 1 year before the screening visit History of 3 or more unexplained consecutive pregnancy losses Active severe or unstable neuropsychiatric SLE Other autoimmune diseases or non-SLE driven inflammatory joint or skin disease or overlap syndromes as primary disease that in the opinion of the investigator will significantly impact the assessment of CLE/SLE disease manifestations and activity  Other protocol-defined inclusion/exclusion criteria apply